ArticleFrontiers in pharmacology2025
Carbapenem-resistant
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Correlation of type 3 secretion system genes with antimicrobial resistance inJournal of Taibah University Medical Sciences · 2026Article
- Genomic and Phenotypic Insights into Carbapenem-ResistantMicroorganisms · 2026Article
- Genotypic and phenotypic landscape of carbapenem-resistant Pseudomonas aeruginosa isolated from respiratory and non-respiratory samples in a tertiary hospital.BMC microbiology · 2026Article
- Molecular epidemiological association between antimicrobial resistance characteristics and type III secretion system in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the relationship between the carriage and expression of virulence genes associated with the type III secretion system (T3SS) in carbapenem-resistant Methods: CRPA strains isolated from the First Hospital Affiliated to Hebei North College between April 2022 and February 2023 were analyzed. Antimicrobial susceptibility was tested using the microbroth dilution method. Second-generation high-throughput sequencing was employed to detect four virulence genes (exoU, exoY, exoS, and exoT) and β-lactamase genes in CRPA strains with T3SS. Multilocus Sequence Typing (MLST) was performed to determine the sequence types (ST) of the strains. The Results: Resistance to imipenem was observed in 100% of the strains, whereas resistance to polymyxin B was the lowest at 6.7%. The highest detection rate of T3SS virulence genes was for exoT (100%), followed by exoS, exoY (88.9%), and exoU (11.1%). Twenty-two ST types were identified, with ST 244 being the most prevalent (31.1%). In the Conclusion: T3SS virulence genes and virulence levels in CRPA strains were correlated with antibiotic resistance. CRPA strains producing blaOXA-101 and blaPER-1 spread throughout the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.